CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
OPERATING EXPENSES
General and administrative	$ 113	$ 225
Research and development	267	157
Total operating expenses	380	382
Interest and other expenses (income), net	15	11
Loss from operations before taxes	395	393
Income tax benefit	(8)	(14)
Net Loss	387	379
Less: Net Loss attributable to the noncontrolling interest	0	0
Net Loss attributable to Capstone Therapeutics Corp. stockholders	$ 387	$ 379
Per Share Information:
Net loss, basic and diluted, attributable to Capstone Therapeutics Corp. stockholders (in dollars per share)	$ 0.01	$ 0.01
Basic and diluted shares outstanding (in shares)	40,885	40,885